当前位置： SCI文献检索 > CANCER CELL期刊下所有文献 > Dragging ras back in the ring.

Dragging ras back in the ring.

Abstract：

:Ras proteins play a major role in human cancers but have not yielded to therapeutic attack. Ras-driven cancers are among the most difficult to treat and often excluded from therapies. The Ras proteins have been termed "undruggable," based on failures from an era in which understanding of signaling transduction, feedback loops, redundancy, tumor heterogeneity, and Ras' oncogenic role was poor. Structures of Ras oncoproteins bound to their effectors or regulators are unsolved, and it is unknown precisely how Ras proteins activate their downstream targets. These knowledge gaps have impaired development of therapeutic strategies. A better understanding of Ras biology and biochemistry, coupled with new ways of targeting undruggable proteins, is likely to lead to new ways of defeating Ras-driven cancers.

journal_name

Cancer Cell

journal_title

Cancer cell

authors

Stephen AG,Esposito D,Bagni RK,McCormick F

doi

10.1016/j.ccr.2014.02.017

subject

Has Abstract

pub_date

2014-03-17 00:00:00

pages

272-81

issue

3

eissn

1535-6108

issn

1878-3686

pii

S1535-6108(14)00081-6

journal_volume

25

pub_type

杂志文章,评审

相关文献

CANCER CELL文献大全
  • A Systematic Framework to Rapidly Obtain Data on Patients with Cancer and COVID-19: CCC19 Governance, Protocol, and Quality Assurance.

    abstract：:When the COVID-19 pandemic began, formal frameworks to collect data about affected patients were lacking. The COVID-19 and Cancer Consortium (CCC19) was formed to collect granular data on patients with cancer and COVID-19 at scale and as rapidly as possible. CCC19 has grown from five initial institutions to 125 instit...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2020.10.022

    authors： COVID-19 and Cancer Consortium. Electronic address: jeremy.warner@vumc.org.,COVID-19 and Cancer Consortium.

    更新日期：2020-12-14 00:00:00

  • Siah2-dependent concerted activity of HIF and FoxA2 regulates formation of neuroendocrine phenotype and neuroendocrine prostate tumors.

    abstract：:Neuroendocrine (NE) phenotype, seen in >30% of prostate adenocarcinomas (PCa), and NE prostate tumors are implicated in aggressive prostate cancer. Formation of NE prostate tumors in the TRAMP mouse model was suppressed in mice lacking the ubiquitin ligase Siah2, which regulates HIF-1alpha availability. Cooperation be...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2010.05.024

    authors： Qi J,Nakayama K,Cardiff RD,Borowsky AD,Kaul K,Williams R,Krajewski S,Mercola D,Carpenter PM,Bowtell D,Ronai ZA

    更新日期：2010-07-13 00:00:00

  • Twist1-induced invadopodia formation promotes tumor metastasis.

    abstract：:The Twist1 transcription factor is known to promote tumor metastasis and induce Epithelial-Mesenchymal Transition (EMT). Here, we report that Twist1 is capable of promoting the formation of invadopodia, specialized membrane protrusions for extracellular matrix degradation. Twist1 induces PDGFRα expression, which in tu...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2011.01.036

    authors： Eckert MA,Lwin TM,Chang AT,Kim J,Danis E,Ohno-Machado L,Yang J

    更新日期：2011-03-08 00:00:00

  • The Platelet Lifeline to Cancer: Challenges and Opportunities.

    abstract：:Besides their function in limiting blood loss and promoting wound healing, experimental evidence has highlighted platelets as active players in all steps of tumorigenesis including tumor growth, tumor cell extravasation, and metastasis. Additionally, thrombocytosis in cancer patients is associated with adverse patient...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/j.ccell.2018.03.002

    authors： Haemmerle M,Stone RL,Menter DG,Afshar-Kharghan V,Sood AK

    更新日期：2018-06-11 00:00:00

  • Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.

    abstract：:T cell engineering is a powerful means to rapidly generate anti-tumor T cells. The costimulatory properties of second-generation chimeric antigen receptors (CARs) determine the overall potency of adoptively transferred T cells. Using an in vivo "stress test" to challenge CD19-targeted T cells, we studied the functiona...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2015.09.004

    authors： Zhao Z,Condomines M,van der Stegen SJC,Perna F,Kloss CC,Gunset G,Plotkin J,Sadelain M

    更新日期：2015-10-12 00:00:00

  • Induction of tumor angiogenesis by Slit-Robo signaling and inhibition of cancer growth by blocking Robo activity.

    abstract：:Slit is a secreted protein known to function through the Roundabout (Robo) receptor as a chemorepellent in axon guidance and neuronal migration, and as an inhibitor in leukocyte chemotaxis. Here we show Slit2 expression in a large number of solid tumors and Robo1 expression in vascular endothelial cells. Recombinant S...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/s1535-6108(03)00164-8

    authors： Wang B,Xiao Y,Ding BB,Zhang N,Yuan Xb,Gui L,Qian KX,Duan S,Chen Z,Rao Y,Geng JG

    更新日期：2003-07-01 00:00:00

  • Leaving home early: reexamination of the canonical models of tumor progression.

    abstract：:A recent report in Science from the Varmus laboratory (Podsypanina et al., 2008) puts an interesting twist on the origins of metastatic cells, suggesting that metastases can arise in ways that are very different from those widely believed. ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2008.09.009

    authors： Weinberg RA

    更新日期：2008-10-07 00:00:00

  • Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression.

    abstract：:Controversy over the role of antioxidants in cancer has persisted for decades. Here, we demonstrate that synthesis of the antioxidant glutathione (GSH), driven by GCLM, is required for cancer initiation. Genetic loss of Gclm prevents a tumor's ability to drive malignant transformation. Intriguingly, these findings can...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2014.11.019

    authors： Harris IS,Treloar AE,Inoue S,Sasaki M,Gorrini C,Lee KC,Yung KY,Brenner D,Knobbe-Thomsen CB,Cox MA,Elia A,Berger T,Cescon DW,Adeoye A,Brüstle A,Molyneux SD,Mason JM,Li WY,Yamamoto K,Wakeham A,Berman HK,Khokha R,

    更新日期：2015-02-09 00:00:00

  • Opening a new GATAway for treating KRAS-driven lung tumors.

    abstract：:In a recent issue of Cell, Kumar and colleagues uncovered a synthetic lethal interaction between oncogenic KRAS and the transcription factor GATA2 in non-small cell lung carcinoma. Pharmacological inhibition of GATA2-mediated pathways with bortezomib and fasudil results in dramatic tumor inhibition. These observations...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2012.04.032

    authors： Barbacid M

    更新日期：2012-05-15 00:00:00

  • When LMO1 Meets MYCN, Neuroblastoma Is Metastatic.

    abstract：:LMO1 is a high-risk neuroblastoma susceptibility gene, but how LMO1 cooperates with MYCN in neuroblastoma tumorigenesis is unclear. In this issue of Cancer Cell, Zhu et al. develop a novel zebrafish model that elucidates a mechanism by which LMO1 and MYCN synergistically initiate neuroblastoma and contribute to metast...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2017.08.014

    authors： Liu Z,Thiele CJ

    更新日期：2017-09-11 00:00:00

  • Identification of CDK10 as an important determinant of resistance to endocrine therapy for breast cancer.

    abstract：:Therapies that target estrogen signaling have transformed the treatment of breast cancer. However, the effectiveness of these agents is limited by the development of resistance. Here, an RNAi screen was used to identify modifiers of tamoxifen sensitivity. We demonstrate that CDK10 is an important determinant of resist...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2008.01.001

    authors： Iorns E,Turner NC,Elliott R,Syed N,Garrone O,Gasco M,Tutt AN,Crook T,Lord CJ,Ashworth A

    更新日期：2008-02-01 00:00:00

  • EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis.

    abstract：:The EZH2 histone methyltransferase mediates the humoral immune response and drives lymphomagenesis through formation of bivalent chromatin domains at critical germinal center (GC) B cell promoters. Herein we show that the actions of EZH2 in driving GC formation and lymphoma precursor lesions require site-specific bind...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2016.07.006

    authors： Béguelin W,Teater M,Gearhart MD,Calvo Fernández MT,Goldstein RL,Cárdenas MG,Hatzi K,Rosen M,Shen H,Corcoran CM,Hamline MY,Gascoyne RD,Levine RL,Abdel-Wahab O,Licht JD,Shaknovich R,Elemento O,Bardwell VJ,Melnick AM

    更新日期：2016-08-08 00:00:00

  • ERK-MAPK signaling opposes Rho-kinase to promote endothelial cell survival and sprouting during angiogenesis.

    abstract：:Inhibition of ERK-MAPK signaling by expression of dominant-negative MEK1 in the tumor vasculature suppresses angiogenesis and tumor growth. In an organotypic tissue culture angiogenesis assay, ERK-MAPK inhibition during the migratory phase results in loss of bipolarity, detachment, and cell death of isolated endotheli...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2005.12.021

    authors： Mavria G,Vercoulen Y,Yeo M,Paterson H,Karasarides M,Marais R,Bird D,Marshall CJ

    更新日期：2006-01-01 00:00:00

  • Is NF-kappaB2/p100 a direct activator of programmed cell death?

    abstract：:Transcription factor NF-kappaB has been implicated in cancer development due to its ability to upregulate expression of genes with potentially prooncogenic functions, such as cell cycle regulators and antiapoptotic proteins (Karin et al., 2002). A recent report by suggests that a structural motif, a death domain (DD),...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/s1535-6108(02)00213-1

    authors： Häcker H,Karin M

    更新日期：2002-12-01 00:00:00

  • PGC1α expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress.

    abstract：:Cancer cells reprogram their metabolism using different strategies to meet energy and anabolic demands to maintain growth and survival. Understanding the molecular and genetic determinants of these metabolic programs is critical to successfully exploit them for therapy. Here, we report that the oncogenic melanocyte li...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.11.020

    authors： Vazquez F,Lim JH,Chim H,Bhalla K,Girnun G,Pierce K,Clish CB,Granter SR,Widlund HR,Spiegelman BM,Puigserver P

    更新日期：2013-03-18 00:00:00

  • TAK1 suppresses a NEMO-dependent but NF-kappaB-independent pathway to liver cancer.

    abstract：:The MAP3-kinase TGF-beta-activated kinase 1 (TAK1) critically modulates innate and adaptive immune responses and connects cytokine stimulation with activation of inflammatory signaling pathways. Here, we report that conditional ablation of TAK1 in liver parenchymal cells (hepatocytes and cholangiocytes) causes hepatoc...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2010.03.021

    authors： Bettermann K,Vucur M,Haybaeck J,Koppe C,Janssen J,Heymann F,Weber A,Weiskirchen R,Liedtke C,Gassler N,Müller M,de Vos R,Wolf MJ,Boege Y,Seleznik GM,Zeller N,Erny D,Fuchs T,Zoller S,Cairo S,Buendia MA,Prinz M,A

    更新日期：2010-05-18 00:00:00

  • Naturally occurring neomorphic PIK3R1 mutations activate the MAPK pathway, dictating therapeutic response to MAPK pathway inhibitors.

    abstract：:PIK3R1 (p85α regulatory subunit of PI3K) is frequently mutated across cancer lineages. Herein, we demonstrate that the most common recurrent PIK3R1 mutation PIK3R1(R348∗) and a nearby mutation PIK3R1(L370fs), in contrast to wild-type and mutations in other regions of PIK3R1, confers an unexpected sensitivity to MEK an...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2014.08.017

    authors： Cheung LW,Yu S,Zhang D,Li J,Ng PK,Panupinthu N,Mitra S,Ju Z,Yu Q,Liang H,Hawke DH,Lu Y,Broaddus RR,Mills GB

    更新日期：2014-10-13 00:00:00

  • The HECT family of E3 ubiquitin ligases: multiple players in cancer development.

    abstract：:The involvement of the homologous to E6-AP carboxyl terminus (HECT)-type E3s in crucial signaling pathways implicated in tumorigenesis is presently an area of intense research and extensive scientific interest. This review highlights recent discoveries on the ubiquitin-mediated degradation of crucial tumor suppressor ...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/j.ccr.2008.06.001

    authors： Bernassola F,Karin M,Ciechanover A,Melino G

    更新日期：2008-07-08 00:00:00

  • PI3K regulatory subunits lose control in cancer.

    abstract：:The PI3K signaling axis is frequently activated in cancer resulting from inactivation of its negative regulator PTEN or activating mutations of the p110alpha catalytic subunit of PI3K. In this issue of Cancer Cell, Jaiswal et al. report that mutations in the p85alpha regulatory subunit of PI3K can also activate this p...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2009.11.017

    authors： Berenjeno IM,Vanhaesebroeck B

    更新日期：2009-12-08 00:00:00

  • Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs.

    abstract：:Current strategies combining anti-angiogenic drugs with chemotherapy provide clinical benefit in cancer patients. It is assumed that anti-angiogenic drugs, such as bevacizumab, transiently normalize abnormal tumor vasculature and contribute to improved delivery of subsequent chemotherapy. To investigate this concept, ...

    journal_title：Cancer cell

    pub_type： 临床试验,杂志文章

    doi：10.1016/j.ccr.2011.11.023

    authors： Van der Veldt AA,Lubberink M,Bahce I,Walraven M,de Boer MP,Greuter HN,Hendrikse NH,Eriksson J,Windhorst AD,Postmus PE,Verheul HM,Serné EH,Lammertsma AA,Smit EF

    更新日期：2012-01-17 00:00:00

  • SnapShot: Immune Checkpoint Inhibitors.

    abstract：:Immunotherapy has changed the landscape of cancer treatment. Checkpoint blockade therapies unleash breaks in the immune system and induce long-lasting responses. However, a significant number of patients do not respond (innate resistance), and a subset progress after responding (acquired resistance). A better understa...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2017.05.010

    authors： Abril-Rodriguez G,Ribas A

    更新日期：2017-06-12 00:00:00

  • Loss of p53 in enterocytes generates an inflammatory microenvironment enabling invasion and lymph node metastasis of carcinogen-induced colorectal tumors.

    abstract：:Loss of p53 is considered to allow progression of colorectal tumors from the adenoma to the carcinoma stage. Using mice with an intestinal epithelial cell (IEC)-specific p53 deletion, we demonstrate that loss of p53 alone is insufficient to initiate intestinal tumorigenesis but markedly enhances carcinogen-induced tum...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2012.11.014

    authors： Schwitalla S,Ziegler PK,Horst D,Becker V,Kerle I,Begus-Nahrmann Y,Lechel A,Rudolph KL,Langer R,Slotta-Huspenina J,Bader FG,Prazeres da Costa O,Neurath MF,Meining A,Kirchner T,Greten FR

    更新日期：2013-01-14 00:00:00

  • Methylome alterations "mark" new therapeutic opportunities in glioblastoma.

    abstract：:In this issue of Cancer Cell, Sturm et al. report that global DNA methylation patterns in glioblastoma multiforme divide adult and pediatric tumors into subgroups that have characteristic DNA mutations, mRNA profiles, and most importantly, different clinical behaviors. These findings suggest novel opportunities for th...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccr.2012.10.001

    authors： Raabe EH,Eberhart CG

    更新日期：2012-10-16 00:00:00

  • Antagonizing Self-Renewal in Acute Myeloid Leukemia: ID2 Takes the Stage.

    abstract：:E proteins and their functional antagonists, the ID proteins, have significant roles in normal hematopoiesis. In this issue of Cancer Cell, Ghisi et al. show that high ID2 levels antagonize self-renewal and promote differentiation of leukemic stem cells in the MLL-translocated molecular subtype of acute myeloid leukem...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2016.06.006

    authors： Deb G,Somervaille TCP

    更新日期：2016-07-11 00:00:00

  • Smoothened variants explain the majority of drug resistance in basal cell carcinoma.

    abstract：:Advanced basal cell carcinomas (BCCs) frequently acquire resistance to Smoothened (SMO) inhibitors through unknown mechanisms. Here we identify SMO mutations in 50% (22 of 44) of resistant BCCs and show that these mutations maintain Hedgehog signaling in the presence of SMO inhibitors. Alterations include four ligand ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccell.2015.02.002

    authors： Atwood SX,Sarin KY,Whitson RJ,Li JR,Kim G,Rezaee M,Ally MS,Kim J,Yao C,Chang AL,Oro AE,Tang JY

    更新日期：2015-03-09 00:00:00

  • Stressing Out about Cancer Immunotherapy.

    abstract：:Stress has long been suspected to negatively influence cancer mortality, yet the molecular mechanisms responsible for this effect have only recently been identified. A new study identifies a stress-induced response in dendritic cells-the activation of the glucocorticoid-inducible transcriptional regulator TSC22D3-as a...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/j.ccell.2019.10.013

    authors： He XY,Ng D,Van Aelst L,Egeblad M

    更新日期：2019-11-11 00:00:00

  • Structural basis for inhibition of the epidermal growth factor receptor by cetuximab.

    abstract：:Recent structural studies of epidermal growth factor receptor (EGFR) family extracellular regions have identified an unexpected mechanism for ligand-induced receptor dimerization that has important implications for activation and inhibition of these receptors. Here we describe the 2.8 angstroms resolution X-ray crysta...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2005.03.003

    authors： Li S,Schmitz KR,Jeffrey PD,Wiltzius JJ,Kussie P,Ferguson KM

    更新日期：2005-04-01 00:00:00

  • The Dual Roles of the Atypical Protein Kinase Cs in Cancer.

    abstract：:Atypical protein kinase C (aPKC) isozymes, PKCλ/ι and PKCζ, are now considered fundamental regulators of tumorigenesis. However, the specific separation of functions that determine their different roles in cancer is still being unraveled. Both aPKCs have pleiotropic context-dependent functions that can translate into ...

    journal_title：Cancer cell

    pub_type： 杂志文章,评审

    doi：10.1016/j.ccell.2019.07.010

    authors： Reina-Campos M,Diaz-Meco MT,Moscat J

    更新日期：2019-09-16 00:00:00

  • Settling a Nervous Stomach: The Neural Regulation of Enteric Cancer.

    abstract：:The nervous system is emerging as a regulator of malignancy. In this issue of Cancer Cell, Hayakawa et al. demonstrate a feedforward signaling loop in which tumor-derived nerve growth factor promotes enteric tumor innervation, and recruited nerves drive cancer growth through acetylcholine-regulated Wnt signaling and s...

    journal_title：Cancer cell

    pub_type： 评论,杂志文章

    doi：10.1016/j.ccell.2016.12.008

    authors： Monje M

    更新日期：2017-01-09 00:00:00

  • Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression.

    abstract：:The molecular mechanisms regulating leukemia-initiating cell (LIC) function are of important clinical significance. We use chronic myelogenous leukemia (CML) as a model of LIC-dependent malignancy and identify the interaction between the ubiquitin ligase Fbw7 and its substrate c-Myc as a regulator of LIC homeostasis. ...

    journal_title：Cancer cell

    pub_type： 杂志文章

    doi：10.1016/j.ccr.2013.01.025

    authors： Reavie L,Buckley SM,Loizou E,Takeishi S,Aranda-Orgilles B,Ndiaye-Lobry D,Abdel-Wahab O,Ibrahim S,Nakayama KI,Aifantis I

    更新日期：2013-03-18 00:00:00